TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01552863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation G, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 5 mg PF-00345439 Formulation TBD, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation H, single dose
Study: NCT02389036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDD Oral Paste
Description: A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
Study: NCT01094821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 3 mg three times daily for 9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule three times daily for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 10 mg ATI-7505 three times daily for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 20 mg ATI-7505 three times daily for 9 days
Study: NCT03610243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Description: Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
Study: NCT00906191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531
Study: NCT00757835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with latanoprost/timolol fixed combination
Description: dosing in the evening with the two fixed combinations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with latanoprost/timolol fixed combination
Description: dosing in the evening with the two fixed combinations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost/timolol fixed combination drops
Description: once in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost/timolol fixed combination drops
Description: once in the evening
Study: NCT04046185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined progesterone
Description: Toripalimab combine with progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: progesterone
Study: NCT02224495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise training
Study: NCT03772574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facemask preoxygenation
Description: Standard facemask preoxygenation
Study: NCT03282292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal jugular vein CVC insertion
Description: Double lumen CVC insertion in the internal jugular vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal jugular vein CVC insertion
Description: Double lumen CVC insertion in the internal jugular vein
Study: NCT03860974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block (single injection)
Description: Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery). For paravertebral blocks without axillary involvement, this will be at the T3 and T5 levels. For paravertebral blocks with axillary involvement, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local anesthetic will be injected per level. For bilateral paravertebral blocks, 8 mL of local anesthetic will be injected per level.
Study: NCT00641797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam 1 - 5mg PO/IV prn
Study: NCT02508636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Given via intramuscular injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
Study: NCT03712410

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PISCES
Description: The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
Study: NCT00962897

Intervention type: PROCEDURE
Intervention: Femoral-popliteal bypass
Description: Surgical bypass of blockage in the thigh
Study: NCT03712410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PISCES
Description: The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PISCES
Description: The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PISCES
Description: The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
Study: NCT00641797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: 25 - 50mg PO/IV once prn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 4 - 8 mg PO/IV prn
Study: NCT02389036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDD Gastric Suspension
Description: 2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Antibiotic
Description: A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
Study: NCT03672292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Description: Oral tablets of SCY-078
Study: NCT00819988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
Study: NCT03672292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole IV vials or oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Voriconazole
Description: Voriconazole IV vials or oral tablets
Study: NCT03007511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fidmi enhanced enteral feeding device
Description: Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
Study: NCT04211337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: Administered orally
Study: NCT02615951

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: Blood sample retrieval for biological and genetic analysis and comparison

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: Blood sample retrieval for biological and genetic analysis and comparison

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: Blood sample retrieval for biological and genetic analysis and comparison

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: Blood sample retrieval for biological and genetic analysis and comparison

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: Blood sample retrieval for biological and genetic analysis and comparison
Study: NCT00962897

Intervention type: PROCEDURE
Intervention: Stent-graft placement
Description: Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
Study: NCT00914615

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
Study: NCT03672292

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Tablets
Description: Oral Placebo Tablets matching SCY-078
Study: NCT05851820

Intervention type: OTHER
Intervention: comparison of outcomes/exposure
Description: analysing if diabetes mellitus have an impact on the primary outcomes: hospital stay, admission to the ICU, death.
Study: NCT03767218

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Late follicular phase stimulation with recombinant-human FSH
Description: Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH \> 10 IU/L, till day of trigger.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Early follicular phase stimulation with recombinant-human FSH
Description: Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
Study: NCT03862391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetics
Description: while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
Study: NCT03728894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam-hydroxyzine with 100% O2
Description: Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam-hydroxyzine with 50% N2O/O2
Description: Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
Study: NCT04804462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Meditation
Description: After donning the VR headset, participants will be able to use a handheld controller to choose from several virtual outdoor settings, three types of meditation, and three session lengths. After choosing their desired option, participants will experience virtual reality meditation in the desired virtual location, of the desired meditation type, and for the allotted duration chosen.
Study: NCT02353247

Intervention type: DRUG
Group type: OTHER
Intervention: Norethindrone acetate
Study: NCT02403245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation
Description: Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music.
Study: NCT01411306

Intervention type: OTHER
Intervention: Toronto Bedside Swallowing Screening Test (TOR-BSST©)
Description: All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.

Intervention type: PROCEDURE
Intervention: Videofluoroscopic Swallow Study
Description: All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
Study: NCT02440386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional economic incentive
Description: Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:~1. Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and~2. send a text message to the study team to let us know they have started ART;~3. Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation.
Study: NCT04488965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Description: Autologous transplant obtained from cortical biopsy
Study: NCT02178384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Altered cast technique
Description: This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision Attachments
Description: These are minor attachments used to split the loading forces during appliance wear

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resilient layer
Description: This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
Study: NCT02213211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether lumefantrine
Study: NCT04116164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In-DOTA-h11B6
Description: 4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
Study: NCT01938274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: A 30-minute discussion and slide presentation with a trained member of the research team.
Study: NCT03811756

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test syrup containing CoQ10 and collagen
Description: Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
Study: NCT01946399

Intervention type: DRUG
Group type: OTHER
Intervention: Ozurdex implant
Description: Intravitreal injection of Dexamethasone implant
Study: NCT03179176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Frequence Ultrasound Doppler (HFUD) utilisation
Description: Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
Study: NCT02385175

Intervention type: OTHER
Intervention: Different objective clinical tests of Eustachian tube function

Intervention type: OTHER
Intervention: Different patient-completed questionnaires relating to Eustachian tube dysfunction
Study: NCT03057028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Study: NCT00925483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dialysis
Description: different dialysis schedules for each arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dialysis
Description: different dialysis schedules for each arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dialysis
Description: different dialysis schedules for each arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dialysis
Description: different dialysis schedules for each arm
Study: NCT01418937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CervarixTM (GSK580299)
Description: Three intramuscular injections
Study: NCT03204513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanderbilt Powered Knee-Ankle Prosthesis
Description: The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microprocessor (MP) Knee Prosthesis
Description: Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
Study: NCT04595864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Description: TAI
Study: NCT02427321

Intervention type: DEVICE
Intervention: Video recording of flexible cystoscopic examination
Description: The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
Study: NCT04306809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered ACT for PTSD and chronic pain
Description: The participants will go through an active internet-based ACT treatment focused on education about PTSD, value-based exposure for the traumatic memory and avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
Study: NCT00273572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Lifestyle Intervention
Description: Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Description: A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
Study: NCT02752009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Sampling Clip
Study: NCT01485211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cross-linking with hypo-osmolar riboflavin
Description: Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
Study: NCT02794233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impedance measurements
Description: Refer to study description
Study: NCT01809912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human apolipoprotein(a) Kringle V
Study: NCT01875146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4x4 min HIT
Description: Conventional 4x4 min high-intensity interval training
Study: NCT03772574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE preoxygenation
Description: Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
Study: NCT01875146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4x4 min HIT + WBV (18 Hz)
Description: 4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4x4 min HIT + (30 Hz)
Description: 4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole-body vibration at 30 Hz
Description: 4x3 min whole-body vibration at 30 Hz